Arrowhead Research Corp (ARWR)

[AliAngel]

www.EquityTradingAlert.com: Stock Alerts For June 4, 2010 Are June 2, 2010 - International Building Technologies Group, Inc. (OTCBB: INBG), June 1, 2010 - Banneker, Inc. (PINKSHEETS: BANI), June 1, 2010 - Angel Acquisition Corp (OTCBB: AGEL), June 1, 2010 - Arrowhead Research Corporation (NASDAQ: ARWR): Sign Up Today!

Jun 04, 2010 (M2 PRESSWIRE via COMTEX) -- www.EquityTradingAlert.com Stock Alerts For June 4, 2010 Are June 2, 2010 - International Building Technologies Group, Inc. (OTCBB: INBG), June 1, 2010 - Banneker, Inc. (PINKSHEETS: BANI), June 1, 2010 - Angel Acquisition Corp (OTCBB: AGEL), June 1, 2010 - Arrowhead Research Corporation (NASDAQ: ARWR)
Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK " "http://www.EquityTradingAlert.com"; www.EquityTradingAlert.com


________________________________________________________________________________

International Building Technologies Group, Inc. Signed a LOI to Enter into a Merger with a China Petroleum Storage Facilities Company with Paid-in Capital of USD8.8 Million and Assets Worth USD54 Million According to a Recent Appraisal

CITY OF INDUSTRY, Calif. June 2, 2010 -- International Building Technologies Group, Inc. (OTCBB:INBG) announced today that it has signed Letter of Intent to merge with FHH Sino New Energies Co., Ltd., a Chinese company ("FHH Sino") located in Weihai, Shandong Province of China. FHH Sino is a petroleum storage company that offers petroleum storage tanks and facilities for rental to the petroleum importer/exporter companies in China. FHH Sino has made a good faith deposit of USD 230,000 with INBG to execute the signed Letter of Intent.

According to recent appraisal prepared by an accounting firm in accordance with China accounting standards, FHH Sino has net assets worth RMB 370 million (approx. USD 54 million) and will generate annual revenues of RMB 100 million (approx. USD 14 million) after its completion of construction of Phase I and execution of signed rental contracts business in early 2011.

Stated Kenneth Yeung, CEO of INBG, "INBG intends to merge with FHH Sino by exchanging INBG's common stock with FHH Sino's holding or subsidiary company. This merger will give INBG the opportunity to switch its nature of business into the energy sector, the ability to generate revenue and profit once the FHH Sino commences its operation in early 2011, thus benefits our shareholders in the near future. FHH Sino is currently in construction of its Phase I with petroleum storage capacity of 320,000 m3 (or approx. 11,300,000 cubic feet) and has completed all the foundation and infrastructure for its 8 storage tanks. This infrastructure includes the supporting facilities and pipeline connecting to the harbor, which is just 600 meters away from the storage facilities. Strategically, this merger will strongly support INBG's ability to connect with the energy market, the potential investors and strategic partners who are interested in participating to the energy sector in the most booming economic of the world, China, and throughout the world ."

About FFH Sino: FHH Sino New Energies Co., Ltd. is a petroleum storage company located in Weihai, a coastal city in Shandong Province of China. The company provides petroleum storage tanks for rental to petroleum companies such as Sinochem and Sino-Petro, as well as being engaged in the business of local fuel oil distribution. It has its approved Phase II planned with the additional storage tanks of 450,000 m3. FHH Sino will be one of the key players in the fuel storage facilities companies for the northern coastal cities of China after the completion of both Phases.

An 8-K along with a copy of the signed and executed LOI specifying all the terms and conditions of the transaction will be filed with the SEC shortly.

This news release may include forward-looking statements within the meaning of section 27A of the United States Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company's analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein.


________________________________________________________________________________

Banneker, Inc. Makes Donation to Benjamin Banneker High School

DENVER, CO June 1, 2010 -- Banneker, Inc. (PINKSHEETS: BANI) donated Banneker's "Class Of" 2010 class rings to this year's graduating seniors of Benjamin Banneker High School in Washington, DC last Friday, May 28. This donation is in line with the 'No Student Left Behind' Program founded by Banneker in 2008. The total donation value to the 2010 Benjamin Banneker High School seniors amounted to $42,250.

"The students of today like flash; eye dazzling jewelry and that is exactly what we created for them. We also wanted to bring these students a message. All of our class jewelry was made in honor of Benjamin Banneker, an African-American clock maker, surveyor, astronomer and early civil-rights activist who made the first entirely wooden clock, among many other accomplishments," CEO Derrick Holmes said. "This great man needs to be known. What he brought to us all needs to be known. In his honor we dedicate each and every piece of jewelry to him."

Pictures and news from the event will be up on Banneker's Facebook page within the week. Follow Banneker Watches on Facebook, Twitter, and YouTube.

About Banneker, Inc.

Banneker is a designer and distributor of unique watches and clocks initially aimed at watch connoisseurs and affluent African-American families. Banneker watches is uniquely positioned to access this market because its name is based on historical figure Benjamin Banneker who is an African-American that created the first clock made in America entirely out of wood. In his honor, all of our timepieces will feature luxury woods.

Banneker was founded on the principle that fashion, elegance, and watch design can all converge together to create not a watch, but a work of art. At Banneker, combining innovation and 'Urban Funk' into all of our products will both satisfy and delight even the most discerning jewelry consumer.


________________________________________________________________________________

Angel Acquisition Corp in Joint Venture Discussions With Premier National IT Consultancy

CARSON CITY, NV J une 1, 2010 -- Angel Acquisition Corp (OTCBB: AGEL) today announced that it has entered into discussions to establish a formal and mutually beneficial joint venture with MSP University (www.mspu.us), one of the nation's premier technology consultancies, to provide training and consultation to entrepreneurs who will launch businesses specializing in information technologies with the help of Angels in Action (www.angelsinaction.tv) micro-loans.

"I want all of our stakeholders to know how truly excited I am about the opportunity to form a strategic partnership with one of the foremost leaders in the information technology industry, MSP University," said Steven Bonenberger, CEO of Angel Acquisition Corp. "Their proven track record of successfully training and/or consulting new upstart IT firms as well as consulting Fortune 100 technology organizations such as Cisco Microsystems, Intel, HP and Microsoft empowers Angel Acquisition Corp. Now, with MSP University, we have access to world-class expertise and resources that advances those technology -- minded entrepreneurs who come to us for help. Each of these will be enhanced in their abilities to successfully get their new businesses off the ground."

Micro-lenders and micro-financing institutions (MFIs) provide loans to recipients that would not otherwise be possible under traditional lending methodologies. The loan amounts generally range from $1,000 to $25,000. These organizations have seen immense growth due to the global economic downturn during the past two years as conventional lending entities struggle to achieve the significant revenue and profit levels that were enjoyed prior to the downturn. Angel Acquisition Corp is dedicating resources, assets and expertise to establish best practices and be a leading provider of micro-finance services and solutions that are geared and focused upon US Based entrepreneurs.

"We look forward to the opportunity to work with Angels in Action," said Gary Beechum, CEO and President of MSP University. "The Department of Labor has identified information technology as the fastest growing sector in the workforce economy. Since most IT firms are small companies, it makes sense for us to collaborate with Angel Acquisition Corp via 'Angels in Action' in providing a platform of development to afford those recipients of micro-loans the best chance to succeed with their new businesses.

"Our clients and sponsors like Intel, Cisco, Ingram Micro, CompTIA and others are looking for new and fresh ideas from the brightest minds that are presently untapped due to the economic conditions we are enduring as a nation. As we as a nation incubate these ideas and nurture these talented entrepreneurs, we will be doing our part in rebuilding our communities and local economies. I anticipate that discussions will proceed quickly and we will soon have a framework in place to unite the efforts of Angel Acquisition Corp and MSP University, bringing all of the resources of both our organizations and our sponsors to bear as we launch this new initiative."

About Angel Acquisition Corp

Angel Acquisition Corp is a diversified asset management company that acquires and/or develops profitable companies. Angel Acquisition Corp either obtains a majority of stock in each company they gain control of or, the company internally develops profitable enterprises. Through the acquisition and development of profitable companies and the expansion of internal divisions, Angel Acquisitions Corp has the ability to experience growth through diverse holdings. Companies turning large profits are analyzed and considered for acquisition. For more information, visit http://www.angelacquisitions.com.

Safe Harbor Statement

From time to time, the Company may issue news releases that contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. For those statements, the Company claims the protection of the safe harbor for forward-looking statement provisions contained in the Private Securities Litigation Reform Act of 1995 and any amendments thereto. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be 'forward-looking statements.' 'Forward-looking statements' are based upon expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those anticipated.


________________________________________________________________________________

Arrowhead Research Announces Clinical Data Presentations at the 2010 ASCO Annual Meeting on June 6, 2010

PASADENA, Calif. June 1, 2010 -- Arrowhead Research Corporation (NASDAQ: ARWR) today announced that interim data from the phase 1 clinical trial conducted by its majority-owned subsidiary, Calando Pharmaceuticals, will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial involves Calando's therapeutic candidate CALAA-01, a formulation of its proprietary delivery system, RONDELTM, and an siRNA sequence targeting cancer. Dr. Antoni Ribas of UCLA's Jonnson Comprehensive Cancer Center will discuss the data in a poster presentation on Sunday, June 6, 2010 at 5:00 p.m. Eastern time.

An abstract with the clinical study data, entitled "Systemic Delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase 1 clinical trial" (Abstract No. 3022) will also be presented at the Developmental Therapeutics - Experimental Therapeutics Session on Sunday, June 6 from 2:00 p.m. to 6:00 p.m. The abstract can be accessed at ASCO's site at: http://abstract.asco.org/AbstView_74_44614.html.

"As the first proof-of-concept data demonstrating systemic siRNA delivery and gene silencing via RNAi in humans, these data represent an important milestone for our Company and for the broader RNAi industry," said Dr. Christopher Anzalone, Arrowhead's Chief Executive Officer. "RONDEL is a flexible delivery system that we believe will ultimately enable multiple RNAi therapeutics, and we are encouraged by what we have seen with CALAA-01."

Dr. Ribas said, "Given the longstanding hurdles with effective systemic delivery of siRNA in humans, these exciting data represent a significant step for the field of RNAi. Detection of RONDEL siRNA nanoparticles inside cells biopsied from tumors demonstrates that RONDEL is capable of shuttling siRNA into tumors after being infused into the bloodstream of patients. We have also seen mRNA and protein knockdown as well as the presence of RONDEL inside tumors in a dose-dependent manner, both of which are excellent indications of effective systemic delivery. While much work remains to be done, these findings suggest that the RONDEL delivery system's approach could be expanded for use as a means for drug delivery and treatment for many cancer therapy targets that are currently considered untreatable."

The Phase I CALAA-001 clinical trial is being conducted at the UCLA Jonsson Comprehensive Cancer Center in Los Angeles, CA and at START (South Texas Accelerated Research Therapeutics) in San Antonio, TX. The trial is an open-label, dose-escalating study of intravenously administered CALAA-01 in adults with solid tumors, who have failed other standard-of-care treatments. In 15 patients treated with CALAA-01 to date, no dose limiting toxicities were observed. One patient at the highest dose level had stable metastatic melanoma for four months, a change from prior course. Biopsies from three patients showed CALAA-01 nanoparticles in tumors in amounts that correlate with dose levels. Additionally, a reduction of target messenger RNA and target protein was observed and at the highest dose, the targeted protein was knocked down with confirmation of mechanism by specific cleavage sequence (RACE-PCR). The study's authors conclude that systemic delivery of siRNA via targeted nanoparticles has been well tolerated and can induce specific, siRNA-mediated gene silencing. The study is ongoing and patients continue to be enrolled at escalating doses. The Company expects to complete the Phase I study by the end of the 2010 calendar year.

About RONDEL

Calando's RONDEL delivery system extends the reach of RNAi therapeutics by answering the new field's most pressing need -- an effective and safe systemic delivery method.

The RONDEL system takes advantage of molecular forces that generate self-assembly of an siRNA containing nanoparticle therapeutic. Comprised of three components and siRNA, the system is engineered to form targeted, stabilized, siRNA-containing nanoparticles of less than 100nm in diameter that target specific tissues and fully protect the siRNA from degradation in serum.

Upon delivery to the target cell, the nanoparticle binds to membrane receptors on the cell surface and the siRNA-containing nanoparticle is taken into the cell by endocytosis. There, chemistry built into the system unpacks the siRNA from the delivery vehicle. The siRNA is deposited into the cytoplasm of the cell where it can access the cellular machinery for RNA interference.

Benefits of the RONDEL system include more effective delivery, modular design to allow easy exchange of the active siRNA ingredient and targeting agent, fewer immune reactions and increased stability. RONDEL is also designed to work with human physiology and cell biology to overcome the extra- and intra-cellular barriers to siRNA delivery.

About CALAA-01

CALAA-01, Calando's leading drug candidate, is a combination of RONDEL(TM) and a patented siRNA targeting the M2 subunit of ribonucleotide reductase, a clinically-validated cancer target. Ribonucleotide reductase catalyzes the conversion of ribonucleosides to deoxyribonucleosides and is necessary for DNA synthesis and replication; it is a critical component in the proliferation of cancer cells. Calando's siRNA and CALAA-01 have demonstrated potent anti-proliferative activity across multiple types of cancer cells. The targeting agent in CALAA-01 is transferrin, a blood plasma protein for iron delivery. Transferrin receptors have been shown to be up regulated in many types of cancer cells.

About the CALAA-01 Phase I Trial

This is an open-label, dose-escalating study of the safety of intravenous CALAA-01 in adults with solid tumors refractory to standard-of-care therapies. Patients who satisfy the inclusion and exclusion criteria receive two, 21-day cycles of CALAA-01. A cycle consists of four infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle is administered consisting of infusions on days 22, 24, 29, and 31 followed by 11 days of rest. For information about the CALAA-01 clinical trials, please visit www.clinicaltrials.gov.

About Arrowhead Research Corporation

Arrowhead Research Corporation (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.

About Calando Pharmaceuticals, Inc.

Calando, a majority-owned subsidiary of Arrowhead Research Corporation, is a clinical stage nanobiotechnology company at the forefront of RNAi therapeutics. Calando develops nanoparticle therapeutics that use patented sugar (cyclodextrin)-based polymer technologies as a drug delivery system for siRNA. Engineered to reduce the debilitating effects of cancer treatment, the proprietary molecules are designed to improve the safety and efficacy of cancer therapeutics using siRNA as the active ingredient. The target-agnostic platform technology has the potential to be applied to a wide range of diseases beyond cancer as well as to therapeutic classes beyond siRNA therapeutics.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that Calando's technology will be successfully developed or that early-stage clinical results will be replicated in larger subsequent trials. Arrowhead Research Corporation's Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-1, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements.


________________________________________________________________________________

About EquityTradingAlert.com

www.EquityTradingAlert.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

www.EquityTradingAlert.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity. To subscribe to this free service, visit the EquityTradingAlert StocksReport home page at http://www.EquityTradingAlert.com and Sign up Free For "Daily Stock Alerts".

Join us at http://www.EquityTradingAlert.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. EquityTradingAlert.com profiles are not a solicitation or recommendation to buy, sell or hold securities. EquityTradingAlert.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. EquityTradingAlert.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), EquityTradingAlert.com is owned and operated by EquityTradingAlert.com Neither EquityTradingAlert.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this press-release, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since EquityTradingAlert.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in EquityTradingAlert.com statements and opinions and such statements and opinions cannot be considered independent. EquityTradingAlert.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. EquityTradingAlert.com services are often paid for using free-trading shares. EquityTradingAlert.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: http://equitytradingalert.com/disclaimer.htm

CONTACT: Ari Goldstein, Equity Trading Alert Tel: [phone] e-mail: [e-mail] WWW: http://www.EquityTradingAlert.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].




(C)1994-2010 M2 COMMUNICATIONS
**********************************************************************
As of Monday, 05-31-2010 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated an UPTREND on 07-30-2009 for ARWR @ $0.48.

For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2010 Comtex News Network, Inc. All rights reserved.

-0-